Herbalife Nutrition collaborated with Syngene to establish it's first nutrition research & development center in India.
Acquisition of Strand Life Sciences’ Systems Biology and Pharma Services Practice Assets: Expansion into Bioinformatics & NGS Services
Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC), our fourth dedicated R&D center.
Crossed an annual turnover of rupees 10,000 Millions .
Syngene listed on BSE(Bombay Stock Exchange) & NSE(National Stock Exchange) of India.
Clinigene International was amalgamated with Syngene.
Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D centre till 2020.
Acceptance of Syngene API manufacturing facility by the Department of Health & Human Services, US Food and Drug Administration.
Established a 75,000 sq. ft. Centre to provide stability and analytical services.
Crossed an annual turnover of Rs 5,000 million.
Baxter International Inc. collaborated with Syngene to establish the ‘Baxter Global Research Center’, our third dedicated R&D centre.
Acceptance of Control Testing Laboratory by the Department of Health & Human Services, US Food and Drug Administration
Abbott collaborated with Syngene to establish Abbott's first nutrition research & development center in India.
Received ANVISA Certification of clinical facilities.
Acquired 100% stake in Clinigene International Limited from Biocon.
Endo Pharmaceuticals USA (NASDAQ: ENDP) signed an agreement to expand their collaboration to develop novel biological therapeutic molecules against cancer.
Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, US Food and Drug Administration.
Expansion of manufacturing services with a new cGMP plant
Initiated operations in safety assessment, formulation development and biologics development services
Bristol-Myers Squibb and our Company signed the first long-term contract to set up our first dedicated R&D Centre
Expansion of 115,000 sq ft of research laboratory as a part of our development program.
Crossed an annual turnover of ₹ 1,000 million.
Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
Forayed into chemical development with a dedicated manufacturing facility.
CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
Granted 100% Export Oriented Unit (EOU) status by the Government of India
Initiated operations as a CRO with services in chemistry and biology